Recent Company News

• 06:13 PM ET Dec 15, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 10:52 AM ET Dec 18, 2025
  

  Truist 2026 Biotech outlook

• 06:08 AM ET Dec 18, 2025
  

  BeOne Medicines appoints Lai Wang to serve as President, Global Head of Research and Development - 8-K ($306.05, 0.00)

• 06:03 AM ET Dec 18, 2025
  

  BeOne Medicines granted U.S. FDA fast track designation for BGB-B2033 as treatment for hepatocellular carcinoma ($306.05, 0.00)

• 09:01 AM ET Dec 15, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 10:08 PM ET Dec 14, 2025
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 08:37 AM ET Dec 09, 2025
  

  BeOne Medicines presents new data from CLL platform for BRUKINSA and BGB-16673 at ASH 2025 ($326.49, 0.00)

• 08:16 AM ET Dec 08, 2025
  

  BeOne Medicines reports new BRUKINSA data featuring a 74% 6-Year PFS in patients with treatment-navee chronic Lymphocytic Leukemia ($322.90, 0.00)

• 08:33 PM ET Dec 07, 2025
  

  StreetAccount China Healthcare Sector Update: China reveals 2025 National Reimbursement Drug List, 114 newly added, 19 made commercial insurance list